US 12,329,433 B2
Systems, devices, and methods for treatment of nasal disorders
Brian Fahey, Menlo Park, CA (US); William Jason Fox, San Mateo, CA (US); Mojgan Saadat, Atherton, CA (US); and Vahid Saadat, Atherton, CA (US)
Assigned to Arrinex, Inc., Redwood City, CA (US)
Appl. No. 17/251,939
Filed by Arrinex, Inc., Redwood City, CA (US)
PCT Filed Jun. 26, 2019, PCT No. PCT/US2019/039199
§ 371(c)(1), (2) Date Dec. 14, 2020,
PCT Pub. No. WO2020/006051, PCT Pub. Date Jan. 2, 2020.
Claims priority of provisional application 62/690,247, filed on Jun. 26, 2018.
Prior Publication US 2021/0369320 A1, Dec. 2, 2021
Int. Cl. A61B 18/18 (2006.01); A61B 18/02 (2006.01); A61B 18/00 (2006.01)
CPC A61B 18/02 (2013.01) [A61B 2018/00214 (2013.01); A61B 2018/00327 (2013.01); A61B 2018/00404 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00583 (2013.01); A61B 2018/00815 (2013.01); A61B 2018/00821 (2013.01); A61B 2018/00994 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A system for treating a nasal condition, the system comprising:
a probe including a shaft and a cryotherapy element coupled to the shaft, wherein the probe is configured to be advanced into a nasal cavity and to cryoablate treatment tissue including at least one nasal nerve at a target treatment site with the cryotherapy element; and
an ultrasound transducer assembly configured to transmit a focused ultrasound beam to non-treatment tissue at a target heating site to increase a temperature of the non-treatment tissue and to protect the non-treatment tissue from effects of cold temperature produced during cryoablation of the treatment tissue.